ES2153964T3 - Liberacion controlada de farmacos administrados por via sublingual o bucal. - Google Patents

Liberacion controlada de farmacos administrados por via sublingual o bucal.

Info

Publication number
ES2153964T3
ES2153964T3 ES96919399T ES96919399T ES2153964T3 ES 2153964 T3 ES2153964 T3 ES 2153964T3 ES 96919399 T ES96919399 T ES 96919399T ES 96919399 T ES96919399 T ES 96919399T ES 2153964 T3 ES2153964 T3 ES 2153964T3
Authority
ES
Spain
Prior art keywords
sublingual
oral
road
controlled release
drugs administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96919399T
Other languages
English (en)
Inventor
Ragab El-Rashidy
Bruce Ronsen
Emad Eldin Hassan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pentech Pharmaceuticals Inc
Original Assignee
Pentech Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentech Pharmaceuticals Inc filed Critical Pentech Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2153964T3 publication Critical patent/ES2153964T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

UNA COMPOSICION QUE PROPORCIONA UNA LIBERACION RELATIVAMENTE LENTA DE FARMACOS HIDROSOLUBLES, TALES COMO LA APOMORFINA, PARA SU ADMINISTRACION POR VIA SUBLINGUAL O BUCAL.
ES96919399T 1995-06-13 1996-06-13 Liberacion controlada de farmacos administrados por via sublingual o bucal. Expired - Lifetime ES2153964T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/489,966 US5624677A (en) 1995-06-13 1995-06-13 Controlled release of drugs delivered by sublingual or buccal administration

Publications (1)

Publication Number Publication Date
ES2153964T3 true ES2153964T3 (es) 2001-03-16

Family

ID=23946020

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96919399T Expired - Lifetime ES2153964T3 (es) 1995-06-13 1996-06-13 Liberacion controlada de farmacos administrados por via sublingual o bucal.

Country Status (10)

Country Link
US (1) US5624677A (es)
EP (1) EP0833619B1 (es)
AT (1) ATE198269T1 (es)
AU (1) AU705488B2 (es)
DE (1) DE69611369T2 (es)
DK (1) DK0833619T3 (es)
ES (1) ES2153964T3 (es)
GR (1) GR3035548T3 (es)
PT (1) PT833619E (es)
WO (1) WO1996041619A1 (es)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888534A (en) * 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9700878D0 (en) 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
US6624200B2 (en) 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
IN186245B (es) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
CA2355117A1 (en) 1998-02-19 1999-08-26 Gabe Soto .beta.-lactam-like chaperone inhibitors
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
US6011035A (en) 1998-06-30 2000-01-04 Neuromed Technologies Inc. Calcium channel blockers
US20020169145A1 (en) * 1998-10-14 2002-11-14 Rajen Shah Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
US6291471B1 (en) * 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males
EP1171134A4 (en) * 1999-03-16 2005-01-05 Pentech Pharmaceuticals Inc CONTROLLED DELIVERY OF SILDENAFIL ADMINISTERED BY SUBLINGUAL OR ORAL
ATE318135T1 (de) 1999-09-03 2006-03-15 Apbi Holdings Llc Verwendung von dapoxetin, a selektiver serotonin- aufnahme inhibitor mit schnellem wirkungseintritt,zur behandlung von sexueller dysfunction
US6841559B1 (en) 1999-11-19 2005-01-11 Washington University Of St. Louis Pyridinones to treat and prevent bacterial infections
CZ20023637A3 (cs) 2000-04-07 2003-02-12 Tap Pharmaceutical Products, Inc. Deriváty apomorfinu a způsoby jejich použití
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
MXPA03007081A (es) * 2001-02-08 2004-10-15 Pharmacia Corp Medicamento de accion rapida para el tratamiento de disfuncion sexual.
US20060127474A1 (en) * 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
US20060073174A1 (en) * 2001-08-16 2006-04-06 Access Pharmaceuticals, Inc. Adherent and erodible film to treat a moist surface of a body tissue
US6585997B2 (en) 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
US20110033542A1 (en) * 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
BR0307473A (pt) * 2002-02-07 2004-11-09 Pharmacia Corp Forma de dosagem farmacêutica para distribuição por via mucosa
US20040005359A1 (en) * 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
GB0221711D0 (en) * 2002-09-19 2002-10-30 Ardana Bioscience Ltd Methods
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7507760B2 (en) * 2004-01-22 2009-03-24 Neuromed Pharmaceuticals Ltd. N-type calcium channel blockers
WO2005102330A2 (en) * 2004-04-16 2005-11-03 Washingtion University Amino methylated 2-pyridinones
US20080064602A1 (en) * 2004-09-09 2008-03-13 Ernest Schay Pharmaceutical Composition
US20070020186A1 (en) 2005-07-22 2007-01-25 Alpex Pharma S.A. Solid dosage formulations of narcotic drugs having improved buccal adsorption
CN101304748A (zh) * 2005-08-22 2008-11-12 加利福尼亚大学董事会 Tlr激动剂
US9265732B2 (en) * 2006-03-06 2016-02-23 Pozen Inc. Dosage forms for administering combinations of drugs
EP2007759A4 (en) * 2006-04-17 2010-12-22 Neuromed Pharmaceuticals Ltd ISOXAZOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS
EP2700638A1 (en) 2006-05-31 2014-02-26 The Regents Of the University of California Purine analogs
DK2061765T3 (en) * 2006-09-01 2015-01-26 Senhwa Biosciences Inc Serine-threonine protein kinase AND PARP-MODULATOR
US20100168103A1 (en) * 2006-09-14 2010-07-01 Neuromed Pharmaceuticals Ltd. Diaryl piperidine compounds as calcium channel blockers
CA2666275A1 (en) * 2006-10-13 2008-04-17 Neuromed Pharmaceuticals Ltd. Cyclopropyl-piperazine compounds as calcium channel blockers
US20090054333A1 (en) * 2006-10-17 2009-02-26 Antonio Giordano Peptide inhibitors of cyclin-dependent kinase activity and uses thereof
ES2456964T3 (es) 2007-02-07 2014-04-24 The Regents Of The University Of California Conjugados de agonistas de TLR sintéticos y usos de los mismos
MX2009010667A (es) * 2007-04-12 2010-02-24 Joyant Pharmaceuticals Inc Dimeros y trimeros mimeticos de smac utiles como agentes anti-cancer.
WO2009002870A1 (en) * 2007-06-22 2008-12-31 Cylene Pharmaceuticals, Inc. Methods for treating aberrant cell proliferation disorders
US20080318939A1 (en) * 2007-06-22 2008-12-25 Whitten Jeffrey P Methods for treating ophthalmic disorders
CA2698463A1 (en) * 2007-08-31 2009-08-06 Cylene Pharmaceuticals, Inc. Therapeutic kinase modulators
WO2009065059A2 (en) 2007-11-14 2009-05-22 Kereos, Inc. Super-oxide dismutase mimetics
US20090155392A1 (en) * 2007-12-17 2009-06-18 Bret David Nelson Methods and Systems for Sublingual Guarana Administration
US7960420B2 (en) * 2007-12-21 2011-06-14 Joyant Pharmaceuticals, Inc Diazonamide analogs with improved solubility
EA201001264A1 (ru) * 2008-02-07 2011-04-29 Дзе Регентс Оф Дзе Юниверсити Оф Калифорния Способ лечения заболеваний мочевого пузыря с помощью активатора tlr7
AU2009219154A1 (en) * 2008-02-29 2009-09-03 Cylene Pharmaceuticals, Inc. Protein kinase modulators
WO2009132452A1 (en) * 2008-04-28 2009-11-05 Neuromed Pharmaceuticals Ltd. Diaryl-cyclylalkyl derivatives as calcium channel blockers
US20090270394A1 (en) * 2008-04-28 2009-10-29 Galemmo Jr Robert Cyclylamine derivatives as calcium channel blockers
US20090270413A1 (en) * 2008-04-28 2009-10-29 Galemmo Jr Robert Di-t-butylphenyl piperazines as calcium channel blockers
JP5123429B2 (ja) * 2008-04-29 2013-01-23 ジョイアント ファーマスーティカルズ、インク． インドリン抗癌剤
US8153619B2 (en) * 2008-05-22 2012-04-10 Joyant Pharmaceuticals, Inc. Diazonamide analogs
US8377968B2 (en) 2008-06-02 2013-02-19 Zalicus Pharmaceuticals, Ltd. N-piperidinyl acetamide derivatives as calcium channel blockers
US9241896B2 (en) 2008-12-19 2016-01-26 Ultragenyx Pharmaceutical Inc. Methods and formulations for treating sialic acid deficiencies
US20130213393A1 (en) 2009-12-22 2013-08-22 Evoke Pharma, Inc. Nasal formulations of metoclopramide
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
SG173617A1 (en) 2009-02-11 2011-09-29 Univ California Toll-like receptor modulators and treatment of diseases
ES2699077T3 (es) 2009-06-12 2019-02-07 Sunovion Pharmaceuticals Inc Apomorfina sublingual
IN2012DN02596A (es) 2009-08-26 2015-08-28 Cylene Pharmaceuticals Inc
EP2784076A1 (en) 2009-10-28 2014-10-01 Joyant Pharmaceuticals, Inc. Dimeric SMAC mimetics
EP2504019A2 (en) 2009-11-25 2012-10-03 ArisGen SA Mucosal delivery composition comprising a peptide complexed with a crown compound and/or a counter ion
CA2782684C (en) 2009-12-04 2018-09-04 Mustapha Haddach Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
AU2011247358B2 (en) 2010-04-30 2014-10-30 Urogen Pharma Ltd. Phospholipid drug analogs
US20120003298A1 (en) 2010-04-30 2012-01-05 Alcide Barberis Methods for inducing an immune response
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
CN103370069A (zh) 2010-07-13 2013-10-23 奥特吉尼克斯制药公司 用于治疗唾液酸缺乏的方法和制剂
US20120083473A1 (en) 2010-09-21 2012-04-05 Johanna Holldack Treatment of conditions by toll-like receptor modulators
JP2013543840A (ja) 2010-10-22 2013-12-09 ユニヴェルシテ・ドゥ・ストラスブール Ｈｓｐ９０関連病態の治療のために有用なポコキシム複合物
NZ612686A (en) 2010-12-16 2015-11-27 Cynapsus Therapeutics Inc Sublingual films
CA2828456C (en) 2011-03-03 2021-05-04 Zalicus Pharmaceuticals Ltd. N-benzl-amino-carboxamide inhibitors of the sodium channel
MX2013010306A (es) * 2011-03-08 2013-12-09 Zalicus Pharmaceuticals Ltd Formulaciones de dispersion solida y metodos de uso de las mismas.
WO2012145255A2 (en) 2011-04-22 2012-10-26 Joyant Pharmaceuticals, Inc. Diazonamide analogs
CN103974965B (zh) 2011-10-24 2019-09-24 奥特吉尼克斯制药公司 唾液酸类似物
EP2903987B1 (en) 2012-10-01 2017-09-20 Urogen Pharma Ltd. Phospholipid drug analogs
WO2014186410A1 (en) 2013-05-13 2014-11-20 NeuOra Microceuticals, LLC Long lasting breath mint
EP3068396B1 (en) 2013-11-11 2019-05-08 Impax Laboratories, Inc. Rapidly disintegrating formulations and methods of use
US9758518B2 (en) 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
RU2729731C2 (ru) 2014-12-15 2020-08-11 Зе Джонс Хопкинс Юниверсити Составы на основе сунитиниба и способы их применения для лечения глазных заболеваний
EP4289950A3 (en) 2015-01-09 2024-01-24 Revolution Medicines, Inc. Macrocyclic compounds that participate in cooperative binding and medical uses thereof
TW201629069A (zh) 2015-01-09 2016-08-16 霍普驅動生物科技股份有限公司 參與協同結合之化合物及其用途
EP3285771A4 (en) 2015-04-21 2018-12-05 Sunovion Pharmaceuticals Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
TW201720803A (zh) 2015-09-14 2017-06-16 超基因克斯製藥公司 唾液酸或其鹽或溶劑合物之晶型
US9989535B2 (en) 2015-10-01 2018-06-05 Warp Drive Bio, Inc. Methods and reagents for analyzing protein-protein interfaces
SG11201803663XA (en) 2015-11-12 2018-05-30 Graybug Vision Inc Aggregating microparticles for therapy
WO2017187183A1 (en) 2016-04-27 2017-11-02 Itara Therapeutics Methods for the identification of bifunctional compounds
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
WO2018112061A1 (en) 2016-12-15 2018-06-21 Evoke Pharma, Inc. Treatment of moderate and severe gastroparesis
BR112019019452A2 (pt) 2017-03-23 2020-04-14 Graybug Vision Inc composto, e, uso de um composto
JP2020512975A (ja) 2017-03-28 2020-04-30 ピメラ，インク． Ｐｏｌ１阻害剤の新規な結晶形態
CN111201040A (zh) 2017-05-10 2020-05-26 灰色视觉公司 用于医学疗法的缓释微粒及其悬浮液
US20200308144A1 (en) 2017-12-20 2020-10-01 Bellicum Pharmaceuticals, Inc. Multimeric piperidine derivatives
AU2019309523A1 (en) 2018-07-27 2021-03-11 Serina Therapeutics, Inc. Cleavable conjugates of catechol compounds and water-soluble polymers and methods of treatment using the same
CN114340670A (zh) 2019-07-11 2022-04-12 普拉克西斯精密药物股份有限公司 T-型钙通道调节剂的制剂及其使用方法
WO2021091982A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
CN115873020A (zh) 2019-11-04 2023-03-31 锐新医药公司 Ras抑制剂
CA3160142A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021108683A1 (en) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
CN115916194A (zh) 2020-06-18 2023-04-04 锐新医药公司 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
PE20231207A1 (es) 2020-09-15 2023-08-17 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer
KR20240004960A (ko) 2021-05-05 2024-01-11 레볼루션 메디슨즈, 인크. Ras 억제제
JP2024516450A (ja) 2021-05-05 2024-04-15 レボリューション メディシンズ インコーポレイテッド 共有結合性ｒａｓ阻害剤及びその使用
IL308195A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors for cancer treatment
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2818855A (en) * 1954-02-11 1958-01-07 Anthony P Miller Surgical device
US3428728A (en) * 1965-10-21 1969-02-18 Hans Lowey Timed release sublingual medications
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
DE3338978A1 (de) * 1982-10-29 1984-05-03 Basf Ag, 6700 Ludwigshafen Verapamil und gallopamil und ihre physiologisch vertraeglichen salze zur resorptiven anwendung auf den schleimhaeuten des mundes, des nasen-rachen-raums und des rektums
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
US5192550A (en) * 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
US5419917A (en) * 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
ATE189121T1 (de) * 1994-04-22 2000-02-15 Pentech Pharmaceuticals Inc Sublinguale dosierungsformen enthaltend apomorphin zur verwendung bei der behandlung von erektiler dysfunktion

Also Published As

Publication number Publication date
US5624677A (en) 1997-04-29
EP0833619A1 (en) 1998-04-08
AU705488B2 (en) 1999-05-20
DE69611369T2 (de) 2001-04-26
DK0833619T3 (da) 2001-01-22
EP0833619A4 (en) 1998-12-30
PT833619E (pt) 2001-04-30
AU6174996A (en) 1997-01-09
WO1996041619A1 (en) 1996-12-27
GR3035548T3 (en) 2001-06-29
EP0833619B1 (en) 2000-12-27
ATE198269T1 (de) 2001-01-15
DE69611369D1 (de) 2001-02-01

Similar Documents

Publication Publication Date Title
ES2153964T3 (es) Liberacion controlada de farmacos administrados por via sublingual o bucal.
TW430562B (en) Controlled release of drugs delivered by sublingual or buccal administration
NZ527867A (en) Oral pharmaceutical composition of cefpodoxime proxetil
UA34428C2 (uk) Заміщені фенілімідазолідини, спосіб їх одержання, фармацевтична композиція, проміжні сполуки
BG104315A (en) Prostaglandine agonists and their application for the treatment of osteal diseases
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
NO963673L (no) Orale vehikkelblandinger
FI980862A0 (fi) Kiraalisia metyylifenyylioksatsolidinoneja
DK0717041T3 (da) Krystallinske paclitaxel-hydrater
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
BRPI0408895A (pt) formulações de cladribina para administração oral e transmucosal aperfeiçoada
BR0207066A (pt) Derivados do 2h-1-benzopirano - processos para sua preparação e composições farmacêuticas a partir deles
AP2001002369A0 (en) Pharmaceutical complex.
DE69802943T2 (de) Arzneizubereitung zur verabreichung von thiocolchicosid durch die mundschleimhaut
PT1052995E (pt) Composicao farmaceutica para a administracao por via nasal de tiocolchicosido
MY142077A (en) Semi-solid systems containing azetidine derivatives
UY26746A1 (es) Liberación controlada de fármacos administrados por via sublingual o bucal
AR023056A1 (es) Composiciones farmaceuticas basadas en alfa-ciclodextrina para la administracion por via oral de analogos de lh-rh
MX9606264A (es) Compuestos de 1-fenil-2-dimetilaminometil-ciclohexan-1-ol como sustancias farmacologicas activas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 833619

Country of ref document: ES